Long lasting growth hormone releasing factor derivatives
A growth hormone and release factor technology, which is used in drug combinations, medical preparations with non-active ingredients, and medical preparations containing active ingredients, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0135] Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp- Ile-Met-Ser-Arg-CONH 2
[0136]Step 1: The synthesis of solid-phase peptides was carried out in the order of 100 μmol. The following protected amino acids were added to the resin: Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Met-OH, Fmoc-Ile-OH, Fmoc-Asp(tBu)-OH, Fmoc -Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu) -OH, Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf )-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-IIe- OH, Fmoc-Ala-OH, Fmoc-Asp(tBu)-OH, Fmoc-Ala-OH, Boc-Tyr(tBu)-OH. They were dissolved into N,N-dimethylformamide (DMF) and, in sequence, using O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate Salt (HBTU) and diisopropylethylamine (DIEA) activation. Removal of the Fmoc protecting gr...
Embodiment 2
[0139] Long-acting derivatives of the GRF peptide of Example 1
[0140] Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp- Ile-Met-Ser-Arg-Lys(MPA)-CONH 2
[0141] Step 1: This step was performed as in Example 1 above, except that the first amino acid added to the resin was Fmoc-Lys(Aloc)-OH.
[0142] Step 2: Selective deprotection of the Lys(Aloc) group was carried out manually and by dissolving in 5 mL C 6 h 6 : CHCl 3 (1:1): 2.5% NMM (v:v): 3 equivalents of Pd(PPh) in 5% AcOH (v:v) 3 ) 4 The solution treated resin was complete in 2 hours. Then the resin was washed with CHCl 3 (6x5 mL), 20% AcOH in DCM (6x5 mL), DCM (6x5 mL) and DMF (6x5 mL) washes.
[0143] Step 3: The synthesis is automated again with the addition of 3-maleimidepropionic acid (MPA). Between each coupling, the resin was washed three times with N,N-dimethylformamide (DMF) and isopropanol, respectively.
[0144] Step 4: Derivatives were cleaved from...
Embodiment 3
[0146] Tyr-(D)ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln -Asp-Ile-Met-Ser-Arg-CONH 2
[0147] Step 1: The synthesis of solid-phase peptides was performed on the order of 100 μmole. The following protected amino acids were added to the resin in sequence with the procedure described in Step 1 of Example 1: Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-MetOH, Fmoc-Ile- OH, Fmoc-Asp(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc- Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)- OH, Fmoc-Phe-OH, Fmoc-Ile-OH, Fmoc-Ala-OH, Fmoc-Asp(tBu)-OH, Fmoc-(D)ala-OH, Boc-Tyr(tBu)-OH.
[0148] Step 2: The implementation of this step is the same as Step 2 of Example 1.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com